Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine

Reuters

Yesterday

Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine

Meiji Seika Pharma Co., Ltd., in collaboration with Arcturus Therapeutics Holdings Inc., has received manufacturing and marketing approval in Japan for a two-dose vial of KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine. This approval, dated August 28, highlights the vaccine's capacity to induce neutralizing antibodies against various SARS-CoV-2 variants, including Omicron sub lineage JN.1 variant XEC, LP.8.1, and the currently circulating XFG and NB.1.8.1. The company plans to begin supplying the vaccine in late September 2025, emphasizing its commitment to combating COVID-19.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-25-001247), on August 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2563498770"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563498770\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563498770?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 18:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563498770","market":"nz","top_or_hot":-1,"title":"Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Meiji Seika Pharma Co., Ltd., in collaboration with Arcturus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Holdings Inc., has received manufacturing and marketing approval in Japan for a two-dose vial of KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine. This approval, dated August 28, highlights the vaccine's capacity to induce neutralizing antibodies against various SARS-CoV-2 variants, including Omicron sub lineage JN.1 variant XEC, LP.8.1, and the currently circulating XFG and NB.1.8.1. The company plans to begin supplying the vaccine in late September 2025, emphasizing its commitment to combating COVID-19.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-25-001247), on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMeiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-29 18:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Meiji Seika Pharma Co., Ltd., in collaboration with Arcturus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Holdings Inc., has received manufacturing and marketing approval in Japan for a two-dose vial of KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine. This approval, dated August 28, highlights the vaccine's capacity to induce neutralizing antibodies against various SARS-CoV-2 variants, including Omicron sub lineage JN.1 variant XEC, LP.8.1, and the currently circulating XFG and NB.1.8.1. The company plans to begin supplying the vaccine in late September 2025, emphasizing its commitment to combating COVID-19.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-25-001247), on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDLbqMHKt:1","article_id":"2563498770","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563498770","pubTimestamp":1756462248,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE, a Self-Amplifying mRNA COVID-19 Vaccine. Meiji Seika Pharma Co., Ltd., in collaboration with Arcturus Therapeutics Holdings Inc., has received manufacturing and marketing approval in Japan for a two-dose vial of KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine. This approval, dated August 28, highlights the vaccine's capacity to induce neutralizing antibodies against various SARS-CoV-2 variants, including Omicron sub lineage JN.1 variant XEC, LP.8.1, and the currently circulating XFG and NB.1.8.1. The company plans to begin supplying the vaccine in late September 2025, emphasizing its commitment to combating COVID-19.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","ARCT":"Arcturus Therapeutics Ltd.","LU0256331488.USD":"SCHRODER ISF GLOBAL ENERGY \"A\" ACC","LU0300736492.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) INC","LU0300736062.USD":"FRANKLIN NATURAL RESOURCES \"A\" (USD) ACC","BK4213":"石油与天然气的勘探与生产","BK4588":"碎股","BK4585":"ETF&股票定投概念","CTRA":"Coterra Energy Inc."},"translate_title":"Meiji Seika Pharma的KOSTAIVE两剂小瓶获得日本监管机构批准®，一种自扩增mRNA新冠疫苗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARCT":0.9,"CTRA":0.9},"content_text":"Meiji Seika Pharma Receives Regulatory Approval in Japan for Two-Dose Vial of KOSTAIVE®, a Self-Amplifying mRNA COVID-19 Vaccine\n    \n\n        Meiji Seika Pharma Co., Ltd., in collaboration with Arcturus Therapeutics Holdings Inc., has received manufacturing and marketing approval in Japan for a two-dose vial of KOSTAIVE®, a self-amplifying mRNA COVID-19 vaccine. This approval, dated August 28, highlights the vaccine's capacity to induce neutralizing antibodies against various SARS-CoV-2 variants, including Omicron sub lineage JN.1 variant XEC, LP.8.1, and the currently circulating XFG and NB.1.8.1. The company plans to begin supplying the vaccine in late September 2025, emphasizing its commitment to combating COVID-19.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcturus Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193805-25-001247), on August 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}